CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF NEOVASCULAR GLAUCOMA
Main Article Content
Abstract
Objective: To describe the clinical characteristics and evaluate the treatment outcomes of neovascular glaucoma at the Glaucoma Department, Vietnam National Eye Hospital.
Subjects and Methods: This prospective interventional case series included 10 patients diagnosed with neovascular glaucoma who were treated at the Glaucoma Department, Vietnam National Eye Hospital, between October 2025 and June 2026. Patients were evaluated before treatment and after a 3-month follow-up. Statistical analysis was performed using SPSS version 27.0.
Results: The study included 10 patients with a mean age of 59.1 ± 16.2 years, of whom 60.0% were older than 60 years. The male-to-female ratio was equal. All patients presented with iris neovascularization, elevated intraocular pressure, and severely impaired vision at admission; 80.0% of eyes had no light perception. Transscleral diode laser cyclophotocoagulation was performed in 90.0% of cases. After 3 months of treatment, the mean intraocular pressure decreased significantly from 47.4 mmHg to 17.7 mmHg (a 62.7% reduction; p < 0.001), while the mean number of intraocular pressure-lowering medications decreased from 4.0 to 0.6. Visual acuity remained stable in most patients, with one patient (10.0%) improving from counting fingers at 1 m to 20/200. Regression of iris neovascularization was observed in 70.0% of patients.
Conclusion: Neovascular glaucoma is a severe ocular disease that is often diagnosed at an advanced stage with profoundly impaired vision. Treatment with transscleral diode laser cyclophotocoagulation effectively reduced intraocular pressure, decreased the need for intraocular pressure-lowering medications, and was associated with regression of iris neovascularization after 3 months of follow-up, while visual acuity remained largely unchanged.
Keywords
neovascular glaucoma, transscleral cyclophotocoagulation, intraocular pressure, visual acuity, treatment outcomes
Article Details
References
2. Pabis-Jakubczyk M, Turno-Kręcicka A, Grzybowski A. Neovascular glaucoma: Etiology, pathogenesis, diagnosis, and treatment. Int J Mol Sci. 2022;23(22):13999. doi:10.3390/ijms232213999.
3. Senthil S, Dada T, Das T, Kaushik S, Puthuran GV, Philip R, et al. Neovascular glaucoma – A review. Indian J Ophthalmol. 2021;69(3):525-534. doi:10.4103/ijo.IJO_1591_20.
4. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases. Ophthalmology. 2008;115(9):1571-1580.
5. Bloom PA, Tsai JC, Sharma K, et al. “Cyclodiode”: Transscleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma. Ophthalmology. 1997;104(9):1508-1519.
6. Schlote T, Derse M, Rassmann K, Nicaeus T, Dietz K, Thiel HJ. Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma. J Glaucoma. 2001;10(4):294-301.
7. Ramji S, Nagi G, Ansari AS, Kailani O. A systematic review and meta-analysis of randomised controlled trials in the management of neovascular glaucoma: absence of consensus and variability in practice. Graefes Arch Clin Exp Ophthalmol. 2023;261(2):477-501. doi:10.1007/s00417-022-05785-5.
8. Rittiphairoj T, Roberti G, Michelessi M. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2023;4:CD007920.
9. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007;26(5):470-485.
10. Sivak-Callcott JA, O’Day DM, Gass JDM, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108(10):1767-1776.